Bioporto A/s · OMXCOP:BIOPOR

Bioporto A/s — Q1 2022 Earnings Presentation

15 slides from Bioporto A/s's earnings presentation, May 11, 2022

  1. Slide 1: Interim Report, Q1 2022

    Interim Report, Q1 2022 May 11, 2022 © Copyright BioPorto

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements References herein to this presentation shall mean and include this document, any oral presentation accompanying this document provided by BioPorto A/S (the “Company” or “BioPorto”), and any further information that may be made available in connection with the subject matte

  3. Slide 3: Agenda

    Agenda 01. Highlights from Q1 2022 02. The NGAL Test Regulatory Studies 03. Q1 2022 financial result 04. Financial Guidance 2022 3

  4. Slide 4: Highlights from Q1 2022

    Highlights from Q1 2022 © Copyright BioPorto 4

  5. Slide 5: Highlights from Q1 2022

    Highlights from Q1 2022 • Strong performance of The NGAL Test – US RUO sales up 116% and global sales up 70% compared to Q1 2021 • Completion of pediatric patient enrollment for US FDA submission on-track for end of Q2 2022 • Strategic focus on preparing BioPorto for US breakthrough • Fully subscrib

  6. Slide 6: Launch an FDA Approved Product in the US

    Launch an FDA Approved Product in the US Strategic Focus Drive NGAL Test Market Strengthen the Company to Attract, Develop & Retain Adoption & Have a Pipeline of Scale & Execute the Best and Brightest High Medical Value Employees Aligned with our Products Values • Complete clinical trials & submit •

  7. Slide 7: Pediatric Trial Enrollment On-track to be Completed end-Q2 2022, Followed by FDA Submission

    Pediatric Trial Enrollment On-track to be Completed end-Q2 2022, To Be Followed by FDA Submission Pediatric study • 15 hospital sites in US clinical trial for The NGAL Test in pediatrics • BioPorto expects to finalize pediatric trial enrollment in 1H 2022, followed by assembling the 1 in 4 affected

  8. Slide 8: Q1 2022 Financial Results

    Q1 2022 Financial Results © Copyright BioPorto 8

  9. Slide 9: 70% Increase in NGAL Test Sales Drives 17% Revenue Growth in Q1 2022 vs. Q1 2021

    70% Increase The NGAL Test Sales Drives 17% Revenue Growth in Q1 2022 vs. Q1 2021 Revenue by Quarter (DKKm) Revenue by Product Category (DKKm) 3.7 2021 Q1 2021 2022 Q2 2022 6.8 3.0 6.5 6.6 5.6 5.3 2.2 1.9 0.9 0.4 0.0 0.0 Q1 Q2 Q3 Q4 NGAL tests Antibodies ELISA kits Royalty & other © Copyright BioPor

  10. Slide 10: Strong Performance of NGAL Sales in the US and ROW

    Strong Performance of The NGAL Test Sales in the US and ROW NGAL Product sales by Quarter (LTM, DKKm) US NGAL 116% NGAL Increase in total revenue from 14 14 +68% 13 13 12 12 14 12 US NGAL sales from Q1 2021 to Q1 2022 11 10 Overall NGAL 70% 10 9 10 Development in global sales of NGAL from Q1 2021 to

  11. Slide 11: DKKm 0.5 Improvement in Adjusted EBITDA Loss; Cash Position Reflects Share Issue Proceeds

    DKKm 0.5 Improvement in Adjusted EBITDA Loss; Cash Position Reflects Share Issue Proceeds Adj. EBITDA and Cash Position (DKKm) Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022* • Cash burn from operations and investments Adj. EBITDA reduced to DKKm 17.1 (Q1 2021: DKKm 21.3) 120.1 Cash position reflecting wor

  12. Slide 12: Fully Subscribed Rights Issue

    Fully Subscribed Rights Issue • 66.9 million new shares at a price of DKK 1.50 per share • Advance subscription commitments and guarantees from institutional investors and three largest shareholders • Proceeds + existing cash will be used to strengthen BioPorto’s capital resources and advance implem

  13. Slide 13: Financial Guidance 2022

    Financial Guidance 2022 © Copyright BioPorto 13

  14. Slide 14: Guidance for 2022: On-track for Execution on Both Strategic & Financial Targets

    Guidance for 2022: On-track for Execution on Both Strategic & Financial Targets Approx. Approx. Approx. EBIT loss loss Adj. EBITDA Revenue EBIT loss DKK 24-26 DKK 95-100 DKK 76-81 million million million BioPorto’s performance and guidance for 2022 is based on certain assumptions described in the an

  15. Slide 15: Financial Calendar 2022

    Financial Calendar 2022 August 17, 2022 Q2 2022 Results November 9, 2022 Q3 2022 Results Contact: Neil Goldman, Executive VP & CFO Tim Eriksen, Investor Relations, Zenith Advisory investor@bioporto.com © Copyright BioPorto

BioPorto — Q1 2022 Earnings Presentation on 6ix